RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Cost-effectiveness of daratumumab plus bortezomib and dexamethasone versus bortezomib plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy
An analysis of the Castor trial
Maiese, E. M., Graham, CN., Hawe, E., Le Moine, J.-G., Abraham, I., & Senbetta, M. (2017). Cost-effectiveness of daratumumab plus bortezomib and dexamethasone versus bortezomib plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy: An analysis of the Castor trial. Blood, 130.
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.